Farnesoid X receptor critically determines the fibrotic response in mice but is expressed to a low extent in human hepatic stellate cells and periductal myofibroblasts.
about
Novel bile acid therapeutics for the treatment of chronic liver diseasesBile acid receptors and nonalcoholic fatty liver diseaseNuclear Receptors as Therapeutic Targets in Liver Disease: Are We There Yet?Recent advances in understanding/management of non-alcoholic steatohepatitis.Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trialRole of nuclear receptor SHP in metabolism and cancer.Bile acids trigger cholemic nephropathy in common bile-duct-ligated mice.Origin of myofibroblasts in the fibrotic liver in miceFunctional characterization of the semisynthetic bile acid derivative INT-767, a dual farnesoid X receptor and TGR5 agonist.Obeticholic acid, a farnesoid X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic rats.Pathobiology of liver fibrosis: a translational success storyMouse models of liver fibrosis mimic human liver fibrosis of different etiologies.Fibrosis in autoimmune and cholestatic liver diseaseHypoxia-inducible factor activation in myeloid cells contributes to the development of liver fibrosis in cholestatic mice.Hepatocarcinogenesis in FXR-/- mice mimics human HCC progression that operates through HNF1α regulation of FXR expressionNovel insight into mechanisms of cholestatic liver injury.Bile Acid Receptors and Liver Cancer.Farnesoid X receptor protects hepatocytes from injury by repressing miR-199a-3p, which increases levels of LKB1.Ciliary subcellular localization of TGR5 determines the cholangiocyte functional response to bile acid signaling.Dual farnesoid X receptor/TGR5 agonist INT-767 reduces liver injury in the Mdr2-/- (Abcb4-/-) mouse cholangiopathy model by promoting biliary HCO⁻₃ outputRecent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME.Bile acids and nonalcoholic fatty liver disease: Molecular insights and therapeutic perspectives.Therapeutic targets in liver fibrosis.Farnesoid x receptor agonists: what they are and how they might be used in treating liver disease.Non-alcoholic Fatty liver disease: the bile Acid-activated farnesoid x receptor as an emerging treatment target.Xenobiotic-induced liver injury and fibrosis.Peroxisome proliferator-activated receptor-γ as a therapeutic target for hepatic fibrosis: from bench to bedside.Bile acid receptors as targets for drug development.Interactions between the intestinal microbiome and liver diseases.The types of hepatic myofibroblasts contributing to liver fibrosis of different etiologies.Role of farnesoid X receptor in inflammation and resolution.Farnesoid X receptor modulators (2011 - 2014): a patent review.Primary biliary cirrhosis: safety and benefits of established and emerging therapies.Obeticholic acid for the treatment of primary biliary cirrhosis.Novel treatment options for portal hypertension.The Role of Nuclear Receptors in the Pathophysiology, Natural Course, and Drug Treatment of NAFLD in Humans.Role of farnesoid X receptor in cholestasis.SHP-dependent and -independent induction of peroxisome proliferator-activated receptor-γ by the bile acid sensor farnesoid X receptor counter-regulates the pro-inflammatory phenotype of liver myofibroblasts.Does the Intestinal Microbiota Explain Differences in the Epidemiology of Liver Disease between East and West?FXR agonist obeticholic acid reduces hepatic inflammation and fibrosis in a rat model of toxic cirrhosis
P2860
Q26748613-73AAE7F8-1E2A-4566-9199-6AB4273C6B78Q26775814-1A500F2A-3731-4360-AF67-C31B454069DEQ28066233-00A3F57B-23D3-4020-95A2-B6439849FF93Q28085689-C4499B48-9849-4AD0-923E-43F5E6D8D987Q28253122-A45B0BA2-519E-45CC-A4FF-91C557FA79ADQ30395192-C2DFA271-F8F6-4A0E-80FD-5D831B62EF88Q34037360-F80B8545-0266-4AAE-91F0-880AD4645256Q34060761-B81A9C8A-F9C1-407A-B5F7-28ACFFD2A79CQ34310071-82182A8A-8083-428D-B1FC-609A16367C24Q34386625-A73FDD61-65CE-46B6-A879-94AFE4D9D796Q34462733-8B38CC65-AF6D-49E1-9EB4-4D0193C43A96Q34482519-68C94E93-A3F2-49AB-90C5-FD4732C78906Q35098677-25A8B9BA-6A51-4BD1-80CE-7503D10157B8Q35913174-90D8D5EB-013D-4CB1-9F72-DBD223993333Q35970148-5DEF9E14-35B0-4469-ACFD-F523AA4BACB5Q36285749-C8AFF165-319E-4C48-94DF-B4FAB2662E81Q36607910-A7E1F202-F4F6-47F1-9FA6-789E04EEC50AQ36626898-3A91A6BC-5AA0-4F36-9F85-899368020C35Q36923647-2244DA5E-380C-4F2D-9EE5-BD9A454E8FF9Q37096585-0C5ED703-07E9-4703-8548-78A9C81E3DE2Q37121662-AACED58C-C4E4-4D94-88BA-1584D752A7BCQ37538343-DA2B6CD7-D3E4-4A9C-BCEC-FF644A81484CQ37828321-4EE29F5A-F4F5-4C63-B114-3605B22243BEQ37957663-A89EF791-E6AC-4768-B8A1-6A3F20794FC7Q37970350-E4829B47-FB2B-4313-8210-75D22EF4BF0BQ37997455-B3365257-B4CA-43C2-83DF-6511BE30A01BQ38018841-AFE13517-EEF9-4F58-9AB3-E4FC2991F653Q38132058-F2337790-8532-4221-BBD1-A098024F9926Q38179779-DE000FB8-A3F3-4607-87A3-7594BCB43D1FQ38237634-AD6B1AE1-1B64-4E3C-A4F6-77487454AF41Q38265728-57F58411-F206-4B43-843C-D100FB8C45A9Q38548688-13A1F8C9-DF2C-4015-B915-628884227B57Q38554677-8A8646BA-B315-40C0-B96A-1469075A1AF8Q38628470-52BA8E56-400A-49EE-9814-3988BBDF5C45Q38680437-C906E023-4224-4C13-9F70-912C841D22FFQ38752520-D9658A96-772E-4E34-B9E8-0D6B1441FB33Q38887864-307FAD3D-75DF-45EF-B2CD-7D8534236E0BQ39600541-1AAF6D8A-E67F-4234-B056-72AA4E5E7076Q40727491-33191395-388E-4E47-A7C0-F89178100BEBQ41107620-CAE610C2-8A4A-416E-B16E-257078747052
P2860
Farnesoid X receptor critically determines the fibrotic response in mice but is expressed to a low extent in human hepatic stellate cells and periductal myofibroblasts.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Farnesoid X receptor criticall ...... and periductal myofibroblasts.
@en
Farnesoid X receptor criticall ...... and periductal myofibroblasts.
@nl
type
label
Farnesoid X receptor criticall ...... and periductal myofibroblasts.
@en
Farnesoid X receptor criticall ...... and periductal myofibroblasts.
@nl
prefLabel
Farnesoid X receptor criticall ...... and periductal myofibroblasts.
@en
Farnesoid X receptor criticall ...... and periductal myofibroblasts.
@nl
P2093
P2860
P50
P1476
Farnesoid X receptor criticall ...... and periductal myofibroblasts.
@en
P2093
Alessandra Caligiuri
Andrea Fuchsbichler
Emil Reisinger
Emina Halilbasic
Gonzalo Carrasco
Hartmut Jaeschke
Helmut Denk
Marco Arrese
Margarita Pizarro
Martin Wagner
P2860
P304
P356
10.2353/AJPATH.2009.090114
P407
P577
2009-11-12T00:00:00Z